There were no associations among steps or TRIMP with plasma biomarkers or cognition. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
There were no associations among steps or TRIMP with plasma biomarkers or cognition. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties. 2 key findings →
Design: randomized controlled trial Participants: 185 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A navigator-centered model can efficiently deliver ATT while supporting structured education, screening, and safety monitoring, potentially contributing to favorable safety outcomes. 1 key finding →
Participants: 243 Evidence: low
Full summary, score breakdown and related studies → Original source
Age ≥ 65 years did not appear to affect the safety considerations of semaglutide. 5 key findings →
Participants: 3,529 Evidence: low
Full summary, score breakdown and related studies → Original source
Women with MCI have greater longitudinal rates of cognitive and functional progression than men. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The innate immune system is a viable target for therapeutic intervention in AD. 5 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings indicate differential relationships between comorbidities (demographic, medical, diagnostic) across NHB, Hispanic, and NHW participants. 5 key findings →
Participants: 764 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Preliminary results do not indicate that TBI or PTSD increase the risk for AD measured by amyloid PET. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We describe the first large-scale, potentially label-enabling clinical trial of a preclinical treatment for ADAD. 4 key findings →
Design: clinical trial Participants: 300 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We applied our procedure to real-world data which include longitudinal in-home monitored walking speed. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The elastic net model that included age, age x sex interaction, allelic APOE terms, and 29 additional SNPs performed the best. 3 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among the 130 articles included in the review, 103 were cognitive training interventions (79%) and 27 were multimodal interventions (21%). 5 key findings →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source
This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. 4 key findings →
Participants: 883 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Survey-based cognitive tests and claims-based dementia diagnosis yielded equal prevalence estimates, yet only half were identified by both measures. 4 key findings →
Participants: 10,450 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. 1 key finding →
Design: clinical trial Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source
Repeated CAD106 administration was generally well tolerated. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Years of experience watching our patients progressively decline and die from complications of Alzheimer's disease (AD) has strongly motivated us to provide newly approved anti-amyloid treatments to appropriate patients. 1 key finding →
Participants: 300 Evidence: low
Full summary, score breakdown and related studies → Original source
In each cohort, achieving just 10-21.4 min/day moderate-to-vigorous PA related to better executive function ( P P = .02). 3 key findings →
Design: cross-sectional Participants: 1,861 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Upon further refinement and validation, the VWD model could inform strategies for dosing and ARIA monitoring in individuals with an ARIA-E history. 1 key finding →
Design: open-label trial Participants: 112 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40). 3 key findings →
Design: clinical trial Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source
Preliminary insights about how clinicians communicate tradeoffs can guide future shared decision-making interventions for mAbs. 3 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
The AD drug development pipeline is slightly larger in 2018 than in 2017. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mortality due to dementia represents a substantial global burden, and is expected to continue to grow into the future as an older, aging population expands globally. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated